CARTER-WALLACE’s ORGANIDIN SHOULD REMAIN ON MARKET WHILE FDA REVIEWS EFFICACY DATA, ADVISORY CMTE. SAYS; "DEAR DOCTOR" LETTER ON CARCINOGENICITY RECOMMENDED

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".